Pfizer and Allergan call off merger; the FDA approves second biosimilar; NEJM comes under fire
Four best-selling drugs in the U.S. had their prices increase by 100% since 2011; Gilead acquires NASH asset; Lilly's unveils CETP inhibitor data
Shire buys Baxalta, creates world's largest rare-disease drugmaker; drug prices continue to climb; immunotherapy coalition is formed
Private equity firm TPG Growth invested in the healthcare services company, which plans to use the funds to expand its capabilities and reach.
The deal not only creates the world's largest drugmaker but also one of the world's largest advertisers.
The consultancy purchased Boomerang Pharmaceutical Communications, its sixth acquisition in the past 12 months.
Pharma M&A expected to continue in 2016; Mylan receives government subpoena about marketing and pricing for doxycycline; KaloBios acquired rights to experimental drug to treat Chagas disease
The deal is estimated to bring in $2 billion in operational synergies, in addition to further commercializing Allergan's products outside the US.
Pfizer/Allergan merger creates world's largest drugmaker; Turing cuts Daraprim price for hospitals; CVS to cover Amgen's PCSK9 inhibitor
AstraZeneca and Sanofi to share compounds in rare agreement; FDA advisory committee votes against bladder cancer drug; Allergan may buyer in Pfizer deal
Pfizer reportedly nears deal with Allergan; health insurers are to blame for rising healthcare costs, according to report; a new fund seeks to invest in digital bio start-ups
Shire said it will acquire Dyax, which markets Kalbitor; Citron doesn't plan to release any additional allegations against Valeant; Myriad Genetics launches social-media campaign
Pfizer in merger talks with Allergan; comparative effectiveness council says PCSK9s aren't worth the money; pharmacy tied to Valeant used "back-door" sales tactics
Walgreens buys Rite Aid in $9.4 billion deal; Arena fires a third of its workforce and discontinues Belviq clinical trials; FDA approves Amgen melanoma immunotherapy
J&J should pursue tuck-in deals; Lilly offers online college course about drug development; Clinton and Sanders identify drugmakers as political enemies
Obama nominates Robert Califf as FDA commissioner; The Huffington Post debuts investigative series on J&J; Amgen acquires cholesterol-lowering drug
Roche CEO sounds off on UK health system cost controls; Concordia Healthcare buys rare-disease drugmaker; Cipla acquires two generic drugmakers
Novartis launches Zarxio, the first US biosimilar; UCB sells its generic business; one-third of children with ADHD are diagnosed before they turn six
The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision
The cloud technology firm announced it will acquire Avalere in a move aimed at growing its relationships with pharma.
Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010
Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company
Havas Health adds PR agency Just:: Health Communications in bid to expand its global footprint.
A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again
AstraZeneca, DigitasLBI New York take top prize in pharma category at Cannes Lions Health; Teva buys a stake in Mylan; Shire tops pharma reputation survey.
Allergan acquires double-chin treatment manufacturer, Kythera, for $2.1 billion; Valeant eyes acquisition of Egyptian drugmaker; worldwide drug sales could reach $1 trillion by 2020
Novartis CEO says pharma must regulate itself; Shire reportedly is in talks to buy biotech Actelion; Lilly insulin outperforms Lantus although safety concerns remain
UK indie shop buys healthcare specialist agency to strengthen media-planning business.
Perrigo says a Mylan deal is possible; new guidelines may reduce cancer screenings; Takeda petitions dictionaries to add a new definition for depression
Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition
Click here to learn about the Agency Issue.
- When it comes to professional ads, print makes its comeback
- Amgen takes issue with yet-to-be published multiple-myeloma drug report
- How Watson for Oncology is advancing cancer care
- Creative partners should push pharma clients to tell better stories
- Retaining talent: How pharma can compete with Google